v3.26.1
Description of Business, Basis of Presentation, and Significant Transactions (Details) - USD ($)
1 Months Ended 3 Months Ended
Mar. 13, 2026
Apr. 30, 2026
Mar. 31, 2026
Mar. 31, 2025
Jul. 12, 2024
Jun. 04, 2024
Feb. 05, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Gain on sale of future royalties, intellectual property, and other assets, net     $ 43,300,000 $ 0      
Common stock registered, shares (in shares)             2,269,721
Aggregate offering price           $ 350,000,000.0  
Sale of future royalties, intellectual property, and other assets, net     $ 43,935,000 $ 0      
ATM Agreement Sales              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Aggregate offering price           $ 75,000,000.0  
JMP | ATM Agreement Sales              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Aggregate offering price         $ 75,000,000.0    
Percentage of aggregate gross sales proceeds         3.00%    
Stock issued (in shares)     0        
Commave Settlement Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Royalty percentage     10.00%        
Commave Settlement Agreement | Commave Therapeutics SA              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sale of future royalties, intellectual property, and other assets, net $ 50,000,000.0            
Commave Settlement Agreement | Commave Therapeutics SA              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Payments to acquire intangible assets     $ 45,000,000.0        
Commave Settlement Agreement | Commave Therapeutics SA | Subsequent Event              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Payments to acquire intangible assets   $ 5,000,000.0          
Commave Settlement Agreement | Commave Therapeutics SA | Aquestive Therapeutics              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Payments to acquire intangible assets     4,500,000        
Commave Settlement Agreement | Commave Therapeutics SA | Aquestive Therapeutics | Subsequent Event              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Payments to acquire intangible assets   500,000          
Commave Settlement Agreement | Commave Therapeutics SA | Zevra Therapeutics              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Payments to acquire intangible assets     $ 40,500,000        
Commave Settlement Agreement | Commave Therapeutics SA | Zevra Therapeutics | Subsequent Event              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Payments to acquire intangible assets   $ 4,500,000          
Commave Settlement Agreement | Aquestive Therapeutics | License              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Royalty percentage     10.00%